Check out the latest cancer-related news and also see who is readily available to offer reliable information, expert commentary, and reaction to today’s headlines.
Contact a media coordinator
Pediatric oncologists from around the world will gather in Lyon, France, from October 23 through 26, for the International Society of Paediatric Oncology’s annual meeting. Featuring new research and important discoveries — many led by MSK Kids researchers — the meeting will highlight the latest in the fields of pediatric oncology, including blood cancer, sarcoma, Wilms’ tumor, genomics, radiation oncology, and neuroblastoma.
Tuesday, October 22, 2019
Scott W. Lowe, PhD, Chair of the Cancer Biology and Genetics Program at the Sloan Kettering Institute (SKI), Howard Hughes Medical Institute Investigator, and Chair of the Geoffrey Beene Cancer Research Center, has been elected to the National Academy of Medicine (NAM), one of the highest honors bestowed upon scientists worldwide.
Monday, October 21, 2019
Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).
Wednesday, October 2, 2019
See all trending topics
MSK award recognizes promising investigators aged 45 or younger at the time of nomination for their efforts in advancing cancer research
Tuesday, November 12, 2019
Memorial Sloan Kettering Cancer Center (MSK) today announced that Claus Torp Jensen, PhD, has joined the institution as its first Chief Digital Officer and Head of Technology.
Monday, October 14, 2019
After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was co-founder of MSK’s Brain Tumor Center during her 30-plus-year tenure at the institution.
Tuesday, September 10, 2019
See all press releases
On Our Blog
Learn about the connection between radon and the risk of lung cancer.
Monday, November 11, 2019
Memorial Sloan Kettering has named three winners of this year’s Paul Marks Prize for Cancer Research, an award that recognizes promising investigators.
Friday, November 8, 2019
A new study reports a possible way to quantify how efficient the immune system is at detecting cancer, and therefore how likely it is that a person will respond to immunotherapy.
Thursday, November 7, 2019
See all blog posts
MSK’s Daniel Heller
and Neil Iyengar
were interviewed about their research at the Making Strides Against Breast Cancer Walk on Sunday.
Sunday, October 20, 2019
Plus, when others should start getting screened based on their level of risk for cancer. MSK’s Melissa Pilewskie
Friday, October 18, 2019
Claus Torp Jensen has joined Memorial Sloan Kettering Cancer Center as its first chief digital officer and head of technology. Before holding executive positions at CVS Health and Aetna, Jensen served in a number of technical leadership roles at IBM and Danske Bank. At MSK, he will report to Chief Operating Officer Kathryn Martin
Tuesday, October 15, 2019
See all media coverage
If you wish to contact MSK about a marketing or advertising related opportunity, or are looking for additional information about our ad campaign, please email us at email@example.com.